These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16061757)

  • 1. Cyclooxygenase inhibition and cardiovascular risk.
    Antman EM; DeMets D; Loscalzo J
    Circulation; 2005 Aug; 112(5):759-70. PubMed ID: 16061757
    [No Abstract]   [Full Text] [Related]  

  • 2. COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?
    Bannwarth B
    Expert Opin Drug Saf; 2006 Jan; 5(1):1-2; author reply 1-2. PubMed ID: 16370948
    [No Abstract]   [Full Text] [Related]  

  • 3. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 4. Valdecoxib: cutaneous and vascular risks.
    Prescrire Int; 2005 Apr; 14(76):63. PubMed ID: 15877326
    [No Abstract]   [Full Text] [Related]  

  • 5. Celecoxib and cardiovascular risks.
    Brophy JM
    Expert Opin Drug Saf; 2005 Nov; 4(6):1005-15. PubMed ID: 16255660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 7. Celecoxib shown effective in preventing colon polyps.
    Nelson NJ
    J Natl Cancer Inst; 2006 May; 98(10):665-7. PubMed ID: 16705118
    [No Abstract]   [Full Text] [Related]  

  • 8. Does celecoxib use increase the risk of cardiovascular events?
    Oviedo JA; Schroy PC
    Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
    [No Abstract]   [Full Text] [Related]  

  • 9. COX-2 inhibitors and the heart: putting risk in perspective.
    Bobadilla RV; Barnett EM; Randels CL
    Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
    [No Abstract]   [Full Text] [Related]  

  • 10. Precaution, cyclooxygenase inhibition, and cardiovascular risk.
    Ritter JM; Harding I; Warren JB
    Trends Pharmacol Sci; 2009 Oct; 30(10):503-8. PubMed ID: 19762092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To the heart of the matter: coxibs, smoking, and cardiovascular risk.
    Hermann M; Krum H; Ruschitzka F
    Circulation; 2005 Aug; 112(7):941-5. PubMed ID: 16103251
    [No Abstract]   [Full Text] [Related]  

  • 12. The emerging cardiovascular risk profile for nonsteroidal anti-inflammatory drugs: implications for clinical nurse specialist practice.
    O'Malley P
    Clin Nurse Spec; 2006; 20(6):277-65. PubMed ID: 17149016
    [No Abstract]   [Full Text] [Related]  

  • 13. Are myocardial infarctions and death in healthy individuals associated with the use of cyclooxygenase inhibitors?
    Renner B; Brune K
    Clin Pharmacol Ther; 2009 Dec; 86(6):599-600; author reply 602-4. PubMed ID: 19421186
    [No Abstract]   [Full Text] [Related]  

  • 14. The Vioxx debacle revisited.
    Daikh DI
    Am J Med; 2005 Sep; 118(9):1057. PubMed ID: 16164908
    [No Abstract]   [Full Text] [Related]  

  • 15. How celecoxib could be safer, how valdecoxib might have been.
    Cohen JS
    Ann Pharmacother; 2005 Sep; 39(9):1542-5. PubMed ID: 16076909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
    Jugdutt BI
    Circulation; 2007 Jan; 115(3):288-91. PubMed ID: 17242292
    [No Abstract]   [Full Text] [Related]  

  • 17. Myocardial infarction and the pill.
    Preston SN
    J Reprod Med; 1976 Jan; 16(1):1-4. PubMed ID: 1255638
    [No Abstract]   [Full Text] [Related]  

  • 18. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    Messerli FH; Sichrovsky T
    Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380
    [No Abstract]   [Full Text] [Related]  

  • 20. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.